Kimberly Skelding, MD
Interventional Cardiology · Wenatchee, WANPI 1225086416
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $35,538 of the $49,312 with a category attached, or 72.1%. Medtronic accounts for 92.2% of it on its own, with 24 other manufacturers making up the rest. 2025 is the largest year on record at $20,652, more than ten times the $1,337 reported in 2019.
Across 391 payments — averaging $126.12 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$45K
- Novartis$2K
- Abbott$528
- Amgen$285
- Actelion Pharmaceuticals US, Inc.$276
- ZOLL Circulation Inc$223
- plus $820 from 19 others
What the payments were for
- Speaking & faculty fees$35,53872%
- Travel & lodging$5,05210%
- Food & beverage$8,72318%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 138 | $45,460 |
| Novartis | 168 | $1,720 |
| Abbott | 9 | $528 |
| Amgen | 17 | $285 |
| Actelion Pharmaceuticals US, Inc. | 18 | $276 |
| ZOLL Circulation Inc | 4 | $223 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 4 | $199 |
| Teleflex LLC | 1 | $131 |
| Johnson & Johnson | 6 | $78 |
| Amarin Pharma, Inc. | 4 | $58 |
| Alnylam Pharmaceuticals Inc. | 2 | $46 |
| Regeneron Healthcare Solutions, Inc. | 2 | $44 |
| United Therapeutics Corporation | 2 | $38 |
| E.r. Squibb & Sons, L.L.C. | 3 | $36 |
| Sanofi-aventis U.S. LLC | 2 | $35 |
| Boehringer Ingelheim | 2 | $25 |
| Baxter Healthcare | 1 | $19 |
| Arbor Pharmaceuticals, Inc. | 1 | $17 |
| Chiesi USA, Inc. | 1 | $15 |
| Organogenesis Inc. | 1 | $15 |
| Preventice Services, LLC | 1 | $14 |
| Irhythm Technologies, Inc. | 1 | $14 |
| Kestra Medical Technology Services, Inc. | 1 | $13 |
| Pfizer | 1 | $11 |
| Kowa Pharmaceuticals America, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- COREVALVE EVOLUT R$39,985
- CoreValve Evolut$161
- MitraClip$135
- GUIDELINER$131
- NAVITOR$120
How this compares
$49,312 in reported general payments places this provider in the 85th percentile of 125 interventional cardiology providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Rosuvastatin Calcium | 18 | $196 |
| Atorvastatin Calcium | 29 | $182 |
| Furosemide | 13 | $45 |
Paid to pharmacies, not to this prescriber.
Other interventional cardiology in Wenatchee
- Brett HiendlmayrWenatchee$27K
- William LombardiSeattle$902K
- Kathleen KearneySeattle$448K
- Robert RileyBellevue$431K
- Danny DvirSeattle$374K
- James McCabeSeattle$289K
- Christopher BrownSeattle$266K
- Lorenzo AzzaliniSeattle$233K
- Sidakpal PanaichSeattle$214K
- Christine ChungSeattle$210K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.